Search Results for: covid-19
Articles
Boehringer Ingelheim & OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in Combination With Anti-PD-1 Antibody Ezabenlimab, in Patients With Advanced Endometrium or Colorectal Tumors October 5, 2021
Boehringer Ingelheim and OSE Immunotherapeutics SA recently announced that the first patient has been dosed in the expansion phase of...Adaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports for Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status October 5, 2021
Adaptive Biotechnologies Corporation recently announced the launch of an enhanced version of its clonoSEQ B-cell Clonality (ID) report, which will...MANUFACTURING SOLUTIONS - Sterile Drug Product Manufacturing During a Global Pandemic October 4, 2021
Ankit Agrawal, MSc, Ronald Aungst, Jr., PhD, Jonothan Hamer, MCIPS, and Barbara Solow, PhD, say with vaccines and treatments now available and yet more on the horizon, the first major manufacturing hurdles have been crossed; however, the finish line is still in the distance.
SYRINGE PLUNGER - Exploring How the Functional Properties of the PremiumCoat® 1-3-mL Plunger Facilitate its Implementation on Filling Lines & Enable the Delivery of Sensitive Vaccines & Biotech Drugs October 4, 2021
Sebastien Cordier, Laure-Hélène Guillemot, PhD, and Audrey Chardonnet explain how the PremiumCoat 1-3-mL syringe plunger combines a pure Bromobutyl formulation with a market-proven ETFE film that acts as a barrier to limit the transfer of rubber leachables into the drug product.
ARTIFICIAL INTELLIGENCE - Attempting to Speed Up Vaccine Development to Combat the Next Pandemic October 4, 2021
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
CONNECTED DELIVERY - Five Perspectives on Connected Drug Delivery Devices October 4, 2021
George I’ons offers insight into the factors driving the development and adoption of connected drug delivery devices and examines the varying perspectives held by relevant healthcare stakeholders.
Evelo Biosciences Announces Positive Phase 2 Clinical Data With EDP1815 in Psoriasis September 28, 2021
Evelo Biosciences, Inc. recently announced positive data from its Phase 2 study evaluating EDP1815 versus placebo for the treatment of mild and moderate psoriasis. A statistically significant reduction in the….
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients With Ulcerative Proctitis & Ulcerative Proctosigmoiditis September 28, 2021
First Wave BioPharma, Inc. recently announced it has begun screening patients for enrollment in a Phase 2b clinical trial investigating...BD Completes Study Investigating Performance of Glass Prefillable Syringes (PFS) in Deep Cold Storage September 22, 2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, completed a preliminary study investigating the impact...AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by US FDA for the Treatment of Relapsed or Recurrent Head & Neck Squamous Cell Carcinoma September 21, 2021
AVEO Oncology recently announced the US FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients...Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration-Resistant Prostate Cancer September 21, 2021
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin (VERU-111) in 80 men...2021 Analytical Testing eBook - Bioanalytical Testing is Fastest Growing Sector September 20, 2021
In this annual Drug Development & Delivery analytical ebook, we present best practices in stability studies as well as the benefits of UPLC optimization…..
Micropore Technologies Announced as a Winner in Heathrow Airport’s Global Britain Business Champion Competition September 20, 2021
Micropore Technologies is a global business that has spent many hundreds of hours travelling across the world from London’s Heathrow...AzurRx BioPharma Announces Acquisition of First Wave Bio & its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications September 15, 2021
AzurRx BioPharma, Inc. recently announced it has entered a definitive agreement to acquire First Wave Bio, Inc. in a stock and cash transaction valued at….
Pii Invests in Expansion of Sterile Fill-Finish Capacity & Capabilities September 15, 2021
Pii has strategically invested in expansion of our sterile fill-finish capacity and capabilities, with production lines capable of supporting large...Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS Following 1 Year Treatment With DCCR September 8, 2021
Soleno Therapeutics, Inc. recently announced top-line results from the company’s ongoing open-label extension study, C602, evaluating investigational, once-daily DCCR (Diazoxide...Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat & Prevent SARS-CoV-2 Infections August 31, 2021
Pardes Biosciences, Inc. recently announced the initiation of a Phase 1 clinical trial, evaluating the company’s lead candidate, PBI-0451 which is being developed as a potential oral….
Jasper Health & BioIntelliSense Form Strategic Collaboration to Transform Remote Monitoring for Oncology Care August 31, 2021
Jasper Health recently announced it has formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its medical grade….
SPECIAL FEATURE - Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021
Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.
DRUG DEVELOPMENT EXECUTIVE - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure August 26, 2021
Eric M. Ostertag, MD, PhD, CEO of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
